Top Arecoline Secrets
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis indivi